Investment Thesis
TG Therapeutics demonstrates impressive revenue growth of 87.3% YoY with respectable 17% operating margins, but this is severely undermined by negative operating cash flow of -$17.9M despite positive net income, coupled with a high debt-to-equity ratio of 1.28x. The disconnect between reported profitability and actual cash generation signals fundamental operational challenges or earnings quality concerns that cannot be overlooked.
Strengths
- Strong top-line growth of 87.3% YoY demonstrating significant revenue momentum and market acceptance
- Solid operating margin of 17% and net margin of 9.7% indicating competitive positioning and pricing power
- Excellent liquidity with current ratio of 5.81x and $442.2M cash balance providing near-term runway
- Strong interest coverage of 15.2x enabling comfortable debt service without financial distress risk
Risks
- Critical negative operating cash flow of -$17.9M despite $19.8M net income indicates severe working capital deterioration or earnings quality issues
- Negative free cash flow of -$17.9M is unsustainable and will erode the cash position if operational cash generation does not reverse immediately
- Elevated leverage with debt-to-equity of 1.28x and $745.1M debt amplifies financial risk if revenue growth slows or cash burn accelerates
- Exceptionally low capital returns (ROE 3.4%, ROA 1.3%) suggest inefficient asset utilization and poor capital deployment despite profitability
Key Metrics to Watch
- Operating cash flow reversal and root cause analysis of OCF/net income divergence in subsequent quarters
- Days sales outstanding (DSO) and accounts receivable trends to assess collection efficiency
- Debt maturity schedule and refinancing requirements given high leverage relative to cash generation
- Gross margin sustainability as revenue scales and competitive intensity increases
Financial Metrics
Revenue
204.9M
Net Income
19.8M
EPS (Diluted)
$0.12
Free Cash Flow
-17.9M
Total Assets
1.5B
Cash
442.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
17.0%
Net Margin
9.7%
ROE
3.4%
ROA
1.3%
FCF Margin
-8.8%
Balance Sheet & Liquidity
Current Ratio
5.81x
Quick Ratio
5.12x
Debt/Equity
1.28x
Debt/Assets
61.9%
Interest Coverage
15.21x
Long-term Debt
745.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T07:44:08.411156 |
Data as of: 2026-03-31 |
Powered by Claude AI